HK Stock Market Move | Pharmaron Beijing (03759) rose by over 7%. The overall performance of the company is accelerating positively, with the amount of new signed orders last year increasing by over 14%.

Pharmaron Beijing (03759) rose more than 7%, as of the time of writing, it rose by 7.12% to HK$20.16, with a turnover of HK$94.7765 million. On the news front, Pharmaron Beijing's 2025 annual performance showed revenue of RMB 14.095 billion, a year-on-year increase of 14.8%; the profit attributable to the parent company was RMB 1.664 billion, a year-on-year decrease of 7.2%. Looking at the fourth quarter alone, in the fourth quarter of 2025, the company's quarterly revenue was RMB 4.009 billion, a year-on-year increase of 15.93%; the net profit attributable to the parent company was RMB 523 million, a year-on-year increase of 40.76%. During the reporting period, the company's laboratory services achieved operating income of RMB 8.1589 billion, a year-on-year increase of 15.8%; the gross profit margin for 2025 was 44.7%. Huatai believes that the overall performance of the company is actively accelerating. The number of customer inquiries continues to improve, with new contract amounts in 25 growing by over 14% year-on-year (further accelerating from over 13% in 1-3Q25). Based on new contract orders and business trends, the company expects revenue in 2026 to grow by 12%-18% year-on-year. Considering the continuous recovery in downstream industry demand, coupled with the strong core business capabilities of the company's laboratory services and the increasing maturity of other business segments, the company is optimistic about achieving positive development in 2026.